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Abstract
Background: While mathematical models are often used to predict progression of cancer and treatment outcomes,
there is still uncertainty over how to best model tumor growth. Seven ordinary differential equation (ODE) models of
tumor growth (exponential, Mendelsohn, logistic, linear, surface, Gompertz, and Bertalanffy) have been proposed, but
there is no clear guidance on how to choose the most appropriate model for a particular cancer.
Methods: We examined all seven of the previously proposed ODE models in the presence and absence of
chemotherapy. We derived equations for the maximum tumor size, doubling time, and the minimum amount of
chemotherapy needed to suppress the tumor and used a sample data set to compare how these quantities differ
based on choice of growth model.
Results: We find that there is a 12-fold difference in predicting doubling times and a 6-fold difference in the
predicted amount of chemotherapy needed for suppression depending on which growth model was used.
Conclusion: Our results highlight the need for careful consideration of model assumptions when developing
mathematical models for use in cancer treatment planning.
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Background
Cancer is a leading cause of death and places a heavy
burden on the health care system due to the chronic
nature of the disease and the side effects caused by many
of the treatments [1–3]. Much research effort is spent
improving the efficacy of current treatments [4] and on
developing new treatment modalitites [5–9]. As cancer
treatment moves towards personalized treatment, math-
ematical models will be important component of this
research, helping to predict the time course of the tumor
and optimizing treatment regimens [10, 11].
Mathematical models are used in a number of ways
to help understand and treat cancer. Models are used to
understand how cancer develops [12] and grows [13–16].
They are used to optimize [17, 18] or even personalize [11,
19, 20] current treatment regimens; predict the efficacy
of new treatments [21] or combinations of different ther-
apies [22–24]; and give insight into the development of
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resistance to treatment [25, 26]. While models have great
potential to improve development and implementation of
cancer treatment, they will only realize this potential if
they provide accurate predictions.
The basis of any mathematical model used to study
treatment of cancer is a model of tumor growth. This
paper focuses on ordinary differential equation (ODE)
models of tumor growth. A number of ODE models have
been proposed to represent tumor growth [27, 28] and are
regularly used to make predictions about the efficacy of
cancer treatments [29]. Unfortunately, choice of a growth
model is often driven by ease of mathematical analysis
rather than whether it provides the best model for growth
of a tumor [27].
Some researchers have attempted to find the “best” ODE
growth model by fitting various models to a small number
of experimental data sets of tumor growth [30–33]. Taken
altogether, the results are rather inconclusive, with results
suggesting that choice of growth model depends at least
in part on the type of tumor [31, 32]. This leaves modelers
with little guidance in choosing a tumor growth model.
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Many researchers realize that improper choice of
growth model is problematic [27] and can lead to dif-
ferences in predictions of treatment outcomes [28, 29].
However, there has not yet been a study that compares
and quantifies differences in predictions of the various
models and how these differences affect predictions of
treatment outcomes. This paper presents results of anal-
ysis of the various ODE growth models highlighting their
predictions of tumor growth in the presence and absence
of chemotherapy. We also fit the models to sample exper-
imental tumor growth data sets and find a wide range of
predicted outcomes based on the choice of growth model.
Methods
Mathematical models
Early studies of tumor growth were concerned with
finding equations to describe the growth of cancer cells
[13–16] and many of the models examined here were pro-
posed at that time. The models predict the growth of a
tumor by describing the change in tumor volume, V, over
time. The model equations used in this analysis are pre-
sented in Table 1 and the models are described below.
a, b, and c are parameters that can be adjusted to describe
a particular data set.
Exponential: In the early stages of tumor growth, cells
divide regularly, creating two daughter cells each time. A
natural description of the early stages of cancer growth
is thus the exponential model [34], where growth is pro-
portional to the population. The proportionality constant
a is the growth rate of the tumor. This model was often
used in early analysis of tumor growth curves [13–16] and
appears to work quite well at predicting early growth. It is
known to fail, however, at later stages when angiogenesis
and nutrient depletion begin to play a role [27, 32].
Mendelsohn: A generalization of the exponential growth
model was introduced by Mendelsohn [35]. In this
model, growth is proportional to some power, b, of the
population.
Table 1 ODE models of tumor growth
Model Equation
Exponential V˙ = aV
Mendelsohn V˙ = aVb




Linear V˙ = aV
(V+b)
Surface V˙ = aV
(V+b) 13
Gompertz V˙ = aV ln b
(V+c)
Bertalanffy V˙ = aV 23 − bV
Logistic: The logistic (or Pearl-Verhulst) equation was
created by Pierre Francois Verhulst in 1838 [36]. This
model describes the growth of a population that is limited
by a carrying capacity of b. The logistic equation assumes
that the growth rate decreases linearly with size until it
equals zero at the carrying capacity.
Linear: The linear model assumes initial exponential
growth that changes to growth that is constant over time.
In our formulation of the model, the initial exponential
growth rate is given by a/b and the later constant growth
is a. The model was used in early research to analyze
growth of cancer cell colonies [16].
Surface: The surface model assumes only a thin layer of
cells at the surface of the tumor are dividing while the
cells inside the solid tumors do not reproduce; they are
mitotically inactive [37]. Our formulation again assumes
exponential growth at early times with the surface growth
taking over at longer times.
Bertalanffy: The Bertalanffy equation was created by
Ludwig Bertalanffy as a model for organism growth [38].
This model assumes that growth occurs proportional to
surface area, but that there is also a decrease of tumor vol-
ume due to cell death. This model was shown to provide
the best description of human tumor growth [30].
Gompertz: Benjamin Gompertz originally created the
Gompertz model in 1825 in order to explain human mor-
tality curves [39]. The model is a generalization of the
logistic model with a sigmoidal curve that is asymmetri-
cal with the point of inflection. The curve was eventually
applied to model growth in size of entire organisms [40]
and more recently, was shown to provide the best fits for
breast and lung cancer growth [32].
Dynamical analysis
Our goal is to assess differences in model predictions.
While we are often concerned with prediction of time
points in the near future, it is also informative to study the
long-term predictions of a mathematical model. To this
end, we find the fixed points of each equation which will
tell us the long-term predictions of each of the models.
Stability analysis [41] is used to determine the boundary
between growth and decay of the tumor.




where λ is the initial growth rate of the tumor. The dou-
bling time is often used as ameasure of how fast the tumor
grows [42]. We use a Taylor expansion of the equations
in Table 1 about V = 0 to determine the initial growth
Murphy et al. BMC Cancer  (2016) 16:163 Page 3 of 10
rate. While this means that the calculated doubling time
is an approximation and only valid during the early por-
tion of the growth phase, many experimental data sets
only follow the growth for a short period of time so this
is representative of what might be calculated in actual
experiments.
Chemotherapy
In addition to assessing the predictions of the growth
models alone, we examined how predictions differed
when chemotherapy was added to the models. This is par-
ticularly important since growth models are often used as
a basis for predicting the efficacy of cancer therapies.
Since this is just illustrative, we choose a simple imple-
mentation of chemotherapy. We assume that there is a
constant supply of drugC0 acting on the tumor.We simply
subtract the term C0V from each equation [29] and again
use stability analysis to determine the conditions that lead
to eradication of the tumor.
Data fitting
Data fromWorschech et al. [43] of a GI-101A xenograft in
nude mice (Figure 1A of [43], control data) was extracted
usingWebPlotDigitizer, an online data extraction tool. Fit-





(xi − mi)2, (2)
where xi are the experimental data points, and mi are the
predicted model values at the same times. The lowest SSR
was found using the Python Scipy fmin_tnc function,
which uses a truncated Newton algorithm.
Since the models have a different number of free param-
eters, comparison using only the SSR is not always fair
since models with more free parameters have more free-
dom to to fit the data. To correct for this bias, we
use Aikaike’s information criterion (AICC), corrected for
small sample size, which penalizes models with more
parameters if there is not enough improvement in the SSR.





+ 2(K + 1)nn − K − 2 , (3)
where n is the number of data points and K is the num-
ber of parameters [44]. The model with the lowest AICC is
considered to be the better model given the experimental
data it is approximating.
Results
Tumor growth in the absence of chemotherapy
A simple analysis of the different models shows that they
have very different predictions of the long-term dynamics
of tumor growth. The fixed points, doubling time and con-
dition for growth of the tumor are presented in Table 2.
All models have two fixed points, one of which is zero.
The remaining fixed point represents the maximum pos-
sible tumor size predicted by the model. In a real system,
the maximum possible tumor size, or carrying capacity,
is a function of the tumor’s environment and its access
to resources [45] and can change as the tumor grows,
particularly in the case of extracapsular extension when
it extends beyond the bounds of its original organ. Four
of the models (exponential, Mendelsohn, linear, and sur-
face) predict that tumors will continue growing without
bound, a biologically unrealistic scenario. The remaining
threemodels (logistic, Gompertz, and Bertalanffy) predict
that tumors will grow to some maximum size and reach a
stable equilibrium at that point.
The growth criteria listed in Table 2 gives the condi-
tion for growth or decay of the tumor if a few cancer
cells appear in the system. While the criteria all have
slightly different forms, they essentially tell us that the
initial growth rate once tumor cells appear must be posi-
tive. All the models agree that if the initial growth rate is
positive, the tumor will continue to grow until it reaches
its maximum size; the disease-free equilibrium is unsta-
ble. The doubling time for each model gives an indication
of how quickly the tumor will reach this maximum size.
Unfortunately, comparing the formulas does not really
give much insight into differences in model predictions
without having some estimate of the parameter values. In
a later section, we give a quantitative assessment of dif-
ferences in model predictions using sample tumor growth
data.
Tumor growth in the presence of chemotherapy
As described in Methods, we assess how chemotherapy
alters the dynamics of each of the growth models using
the simplifying assumption of constant drug concentra-
tion.We again use stability analysis to assess the long-term
Table 2 Model predictions in the absence of chemotherapy
Model Maximum Doubling Growth
size time condition
Exponential ∞ ln 2a a > 0
Mendelsohn ∞ ln 2a a > 0
Logistic b ln 2a a > 0

























a−b a − b > 0
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predictions made by each of the models. Each of the
models again predicts that there are two possible fixed
points, one of which is zero. The other fixed point repre-
sents the maximum possible tumor size in the presence
of chemotherapy and is presented in Table 3. In this case,
only one model (exponential) predicts that the tumor
will continue to grow indefinitely even in the presence
of chemotherapy. The remaining models all predict that
the chemotherapy will hold the tumor to some maximum
size. Unfortunately, it is again difficult to assess the rela-
tive sizes of the predicted maximum size without having
values for parameters.
We can again determine the boundary condition that
delineates growth of the tumor from decay of the
tumor. In this case, this represents the minimum amount
of chemotherapy needed to cause eradication of the
tumor. Essentially, the minimum amount of chemother-
apy needed is the amount that results in a kill rate equal to
the initial growth rate of the tumor.
Quantitative example
In the previous sections, we derived equations for maxi-
mum tumor size and conditions for growth of the tumor
in the presence and absence of chemotherapy for each
of the ODE growth models. However, it is difficult to
assess just how large differences between model predic-
tions are without having values for model parameters. In
this section, we use sample tumor growth data extracted
from the literature to quantitatively assess differences in
model predictions.
We use data from Worschech et al. [43] which consists
of measurements of growth of GI-101A cells injected sub-
cutaneously into nude mice. This is an unusually long data
set consisting of 14 time points spanning 114 days. In
addition to assessing differences in model predictions, we
will use this data set to examine whether model predic-
tions can be improved with the collection of more data.
We will initially use only the first half of the time series,
Table 3 Model predictions in the presence of chemotherapy
Model Maximum Minimum concentration
size needed to cure








Logistic b(a−C0)a C0 = a






















C0 = a − b
seven points spanning 65 days. Note that many tumor
growth data sets contain fewer than ten points and often
span only a week or two [31], so this truncated data set is
quite representative of much of the data available in the
literature.
Model fits to this truncated data, along with the best
fit parameter estimates are presented in Fig. 1. All the
models provide reasonable fits to the data, with the expo-
nential model producing the worst SSR since it only has
one free parameter. The model with the lowest SSR is
the Bertalanffy model in this case. However, the AICC
indicates that the exponential model actually provides the
best explanation for the data since the improvement in
SSR did not offset the inherent improvement in fit with
the addition of the extra parameter. A close inspection of
the fits shows that they largely agree on the growth tra-
jectory while there are experimental data points to guide
the time course, but they appear to diverge beyond the
last experimentally collected time point. This is partic-
ularly problematic since mathematical models are often
used for extrapolation, suggesting that proper choice of
growth model is extremely important for correctly pre-
dicting the future growth of tumors as well as for assessing
how treatment might affect growth of the tumor.
As a test of the accuracy of each model, we can use
the best fit parameter estimates from the truncated data
to predict the remaining seven time points of the full
data set. As a measure of the accuracy of the predictions,
we can calculate the SSR for each model prediction. The
model predictions, along with the SSRs, are presented in
Fig. 2. While the model that provided the best fit to the
data was the Bertalanffy model and the model that pro-
vided the best explanation for the data was the exponential
model, the model that actually provides the best estimate
of the future growth of the tumor is the surface model.
This is likely because the experimental data are measure-
ments of a xenograft which grows as an approximately
spherical tumor where only the cells near the surface are
dividing. With the exception of the exponential model,
the models underestimate the actual growth of the tumor.
In the case of the Bertalanffy, Gompertz, and logistic
models, this is because the truncated data set did not pro-
vide enough information to correctly estimate the max-
imum tumor size. Unfortunately, these three models are
particularly popular choices for modeling tumor growth
[27, 29] because they include a biologically realistic slow-
ing of the growth rate as the tumor increases. Yet it is
precisely this feature that results in the poor predictive
value of the models.
In practice, mathematical models are often not used to
predict full time series, but are used to calculate quanti-
ties of interest to clinicians. Using the formulas derived in
sections “Tumor growth in the absence of chemotherapy”
and “Tumor growth in the presence of chemotherapy”, we
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Fig. 1Model fits to data. Best fits of the ODE tumor growth models to the first half of the data from Worschech et al. [43]. Parameter estimates are
given in the table below the graph
can use our parameter estimates to calculate maximum
tumor size, doubling time, and minimum concentration
of chemotherapy needed for suppression of the tumor.
These quantities are presented in Fig. 4 (top row) for the
truncated Worschech data. Four of the models (exponen-
tial, Mendelsohn, linear, and surface) predict indefinite
growth of the tumor. The remaining three models pre-
dict finite tumor sizes, but the predicted maximum size
varies by almost an order of magnitude, with the Gom-
pertz and logistic models estimating a maximum tumor
volume of ∼ 2000mm3 while the Bertalanffy model esti-
mates a maximum tumor volume of ∼ 16000mm3. The
doubling time estimated by the different models also
shows a good deal of variation, ranging from ∼ 2 d for
the Mendelsohn and Bertalanffy models to ∼ 26 d for
the exponential model. The assumption of exponential
growth underlies many calculations of the tumor growth
rate or doubling time [42, 46] and the exponential model
is also the model of choice for this data, so it is con-
cerning that the exponential model provides one of the
extreme estimates of doubling time. Of particular concern
is the variation in predictions of the minimum amount
of chemotherapy needed to suppress a tumor. The Berta-
lanffy and Mendelsohn models predictions are about six
times larger than the predictions of the remaining mod-
els. If we use one of these models to decide on treatment
plans, we could be treating patients with far more drug
than is actually necessary. The extreme values predicted
by the Bertalanffy model are especially concerning since
the Bertalanffy model provided the lowest SSR and might
be a choice for some modelers in predicting the future
growth of this particular tumor.
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Fig. 2 ODE models’ predicted time course of tumor growth. Each model was fit to the first seven time points and parameter estimates were used to
extrapolate the remaining seven time points. The SSR for each prediction is given in the table below the graph
Given that the short time series led to a large varia-
tion in predicted outcomes, we examined whether the
collection of extra time points might lead the models to
more closely agree on predicted outcomes. We fit the
full Worschech time series with each of the ODE growth
models, as shown in Fig. 3. Many of the estimated param-
eter values change somewhat from the estimates deter-
mined by the fits to the first half of the time series. The
most notable of these is the second parameter (b) of the
Bertalanffy model which drops to essentially zero, sug-
gesting that the best description of the data by this model
neglects death within the core of the tumor. The model
with the best fit in this case is the logistic model, which
has both the lowest SSR and lowest AICC , so the addi-
tion of extra information can alter the choice of growth
model. Again, however, we see that the models all pro-
vide reasonably good fits to the experimental data, but
start to diverge beyond the last data point. It is unclear
if this divergence will lead to large variations in clinical
parameters.
The maximum tumor size, doubling time and mini-
mum amount of chemotherapy needed for suppression
predicted by each model based on parameter estimates
from the full Worschech time series are shown in Fig. 4
(center row). As before, four of the models predict unfet-
tered growth of the tumor, but they are now joined by
the Bertalanffy model in predicting unrealistically large
tumors. Since there is now essentially no death of tumor
cells in the Bertalanffy model, the tumor continues to
grow indefinitely. The maximum tumor sizes predicted by
the Gompertz and logistic models have increased slightly
to ∼ 5000 mm3 and ∼ 7000 mm3, respectively. This is
because the new data clearly shows that the tumor does
not stop growing at 2000 mm3. The doubling times pre-
dicted by the Mendelsohn and Bertalanffy models are still
quite a bit smaller than those predicted by the remaining
models, although these estimates have increased. Finally,
the predicted amount of chemotherapy needed to sup-
press the tumor by the Mendelsohn model drops, coming
noticeably closer to the values predicted by all but the
Bertalanffy model.
To quantify the changes we see with the addition of extra
time points, we calculate the percent difference in each
prediction between estimates based on the truncated time
series and estimates based on the full time series (Fig. 4,
bottom row). Of those models that predict a finite tumor
size, we see that all have increased the predicted size of
the tumor. The predicted doubling time has also increased
for all of the models. This suggests that all of the models
were underestimating the true doubling time of the tumor.
Similarly, the percent differences suggest that the mod-
els all overestimated the amount of chemotherapy needed
to suppress the tumor. The Mendelsohn and Bertalanffy
models, which predicted particularly small doubling times
and large amount of chemotherapy, show the largest per-
cent changes in both estimates with the addition of extra
time points. The surface model, which most accurately
predicted the full time course based on estimates from
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Fig. 3Model fits to data. Best fits of the ODE tumor growth models to the data from Worschech et al. [43]. Parameter estimates are given in the
table below the graph
the first half, shows the smallest percent change with the
addition of extra time points.
Discussion
This paper examines several commonly used ODEmodels
of tumor growth and quantitatively assesses the differ-
ences in their predictions of clinically relevant quantities.
We first derived equations for the maximum tumor size,
doubling time, and the condition for growth of all the
models. We then derived equations for the maximum
tumor size in the presence of chemotherapy and the min-
imum amount of chemotherapy needed to suppress a
tumor. Finally, we used experimental tumor growth data
along with these equations to compare predicted values
of maximum tumor size, doubling time, and minimum
amount of chemotherapy needed for suppression for each
of the ODE models. We find that there is a six-fold
difference in the minimum concentration of chemother-
apy required for suppression of the tumor and a 12-fold
difference in estimates of the doubling time. While the
exact amount of variation in predictions between different
models will differ for other data sets, we expect that there
will be disagreement in model predictions for all data sets.
In fact, this data set was particularly long, so the models
were constrained to agree for a longer time period than
with most other data sets. This, along with our finding
that increasing the duration of the data set reduced the
variability in model predictions suggests that differences
in model predictions might be even larger for most other
data sets. These findings suggest that modelers and clini-
ciansmust carefully consider their choice of growthmodel
and how different growth assumptions might alter model
predictions of the efficacy of treatment.
While our findings could be dismissed because they are
based on a single example or because the models and the
implementation of chemotherapy are highly simplified,
we believe they highlight a significant problem. While
many mathematical models used for clinical assessment
Murphy et al. BMC Cancer  (2016) 16:163 Page 8 of 10























































































































































































Fig. 4 Estimates of clinically important measurements. Model predictions of the maximum tumor volume (left), doubling time (center), and
minimum concentration of chemotherapy needed for eradication (right) based on parameter estimates from the half (top row) or the full (center
row) Worschech data set. The bottom row shows the percent change in each of the predictions when the full data set is used rather than the
truncated data set
of patients and development of radiation or chemother-
apy plans are more complex than those presented here
[47], they must all make some assumption of how the
tumor will grow. Due to the complexity of these models,
however, it is difficult to trace the effect of the choice of
growth model and determine how this choice might alter
the model’s predictions. In fact, while model predictions
are often assessed for sensitivity to errors in estimates of
the parameters [48, 49], the effect of model assumptions
is often neglected. Our findings, however, indicate that
these assumptions could have a profound effect on model
predictions since our simple models show that different
choices of growthmodel result in large variations inmodel
predictions. The results of these inaccuracies could have
significant impacts on patient outcomes since we might
either provide too much treatment, causing more severe
side effects, or too little treatment, possibly resulting in
continued growth of the tumor. In fact, a recent analysis
of patients receiving radiation therapy suggests that tumor
size relative to its maximum possible size is a stronger
indicator of response to treatment than simply the tumor
size [50]. This is because the radiosensitivity of tumor cells
is dependent on their growth and tumors closer to their
maximum size are growing more slowly than tumors that
still have room to grow. This simply highlights the need
to accurately determine how tumors are growing when
planning for dose and fractionation schedule.
While some research has attempted to find the best
ODEmodel to describe tumor growth [30–33], the results
seem to suggest that there are no broad guidelines; the
most appropriate model seems to be dependent on the
details of the experiment. These papers used least-square
minimization, or minimization of information criterion
to determine the “best” model [44]. In our example, use
of minimum SSR would lead us to choose the Berta-
lanffy model as the “best” model, while use of AICC would
lead us to choose the exponential model to fit the trun-
cated Worschech data set. However, further investigation
suggests that either of these models would actually be a
poor choice of model. The Bertalanffy did a poor job of
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predicting the future growth of the tumor (Fig. 2), and
gave an extremely low estimate of the doubling time and a
high estimate for the amount of chemotherapy needed to
suppress the tumor. The exponential model overestimated
the growth rate of the tumor and does not allow for slower
growth of the tumor as resources are depleted.
While some modelers would perhaps fit several differ-
ent growth models to a data set, current model selection
techniques were not designed for the type of model selec-
tion problem faced by cancer modelers. Statistical mea-
sures such as the SSR, AICC , Mallow’s Cp [51], Schwarz
Bayesian information criterion [52], among others, all
measure how well the model explains experimental data
that has already been collected. A model selected as the
best model using one of these measures should work
reasonably well to make predictions if future behavior
is similar to past behavior. Unfortunately, we know that
this is often not the case when modeling tumor growth.
Most experimental data sets capture the early growth of
the tumor [31]. Modelers, however, would like to pre-
dict future growth where space and resource limitations
hamper growth and structural changes such as a necrotic
core, extracapsular extension, and angiogenesis will also
affect growth dynamics [53–55], so the data used to select
the model does not necessarily reflect the dynamics at
the time when the predictions are made. In addition, it is
well-known that experimental results in many pre-clinical
systems do not translate well to human clinical studies
[56–59]. A model chosen based on goodness-of-fit cri-
teria to data from a pre-clinical experiment might not
provide the most accurate predictions of future growth
and treatment outcomes in humans. Our example sug-
gests that more robust testing of model assumptions is
needed before settling on a particular formulation. Min-
imization of SSR or information criterion does not guar-
antee selection of the best model for predicting future
behavior.
Conclusions
Our results show that choice of tumor growth model
can lead to as much as a 12-fold change in predicted
outcomes and that the model that best fits experimen-
tal data might not be the model that best predicts future
growth. It is our hope that the findings presented here will
spur more investigation into the effect of choice of can-
cer growth model on predicted treatment outcomes and
that researchers will consider more than just best fit when
selecting a growth model.
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